| Name | Title | Contact Details |
|---|
Partnering with more than 1,800 physicians at more than 235 outpatient surgery centers across the United States, AmSurg is the nationally recognized leader in the development, management and operation of outpatient surgery centers. AmSurg surgery centers provide high quality, low cost surgical services with superior patient satisfaction. We believe in empowering our physician partners to achieve their professional and personal goals by providing innovative operational, clinical and strategic services.
Myocor is a Osseo, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Burbank HealthCare Foundation is a Burbank, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ebenezer Ridges is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Sernova Corp. is a clinical-stage biotechnology company that is developing its Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells, for the treatment of chronic diseases such as insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. On implantation, the Cell Pouch forms a natural vascularized tissue environment in the body for the long-term survival and function of therapeutic cells that release essential factors absent or deficient in patients with certain chronic diseases. Sernova is also advancing a proprietary technology to shield therapeutic cells from immune system attacks with the goal to eliminate the need for chronic, systemic immunosuppression. In May 2022, the Company announced a global strategic partnership with Evotec, providing Sernova with a potentially unlimited supply of insulin-producing islet cells to treat patients with insulin-dependent diabetes (type 1 and type 2). Sernova continues to progress additional development programs utilizing its Cell Pouch System: a cell therapy for hypothyroid disease resulting from thyroid gland removal and an ex-vivo lentiviral Factor VIII gene therapy for hemophilia A.